Chinese Herbal Medicine (Yiqi-Yangyin-Jiedu Decoction) Combined With Osimertinib as First-Line Treatment in EGFR Mutation-Positive Advanced Non-Small-Cell Lung Cancer (CATLA-2): A Study Protocol for a Double-Blind Randomized Controlled Trial

Background: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (EGFR-TKIs) significantly improve the prognosis of non-small cell lung cancer (NSCLC) with EGFR mutation-positive. Although third-generation EGFR-TKI osimertinib is demonstrated with superior efficacy compared with first-...

Descripción completa

Detalles Bibliográficos
Autores principales: Yao, Jialin, Lu, Yan, Jiao, Lijing, Bi, Ling, Yang, Wenxiao, Su, Lingzi, Shi, Jun, Wang, Zhe, Gong, Yabin, Xu, Ling
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9010724/
https://www.ncbi.nlm.nih.gov/pubmed/35431966
http://dx.doi.org/10.3389/fphar.2022.840889

Ejemplares similares

Ejemplares similares